Difference between revisions of "Waldenström macroglobulinemia"
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
=Relapsed/Refractory= | =Relapsed/Refractory= | ||
| + | |||
| + | ==Bortezomib and Rituximab== | ||
| + | |||
| + | ===Regimen=== | ||
| + | *[[Bortezomib (Velcade)]] 1.6 mg/m2 IV days 1, 8, 15 | ||
| + | *[[Rituximab (Rituxan)]] 375 mg/m2 IV on days 1, 8, 15, 22 (cycles 1 and 4, only) | ||
| + | |||
| + | '''28-day cycles x up to 6 cycles''' | ||
| + | |||
| + | ===References=== | ||
| + | # Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10;28(8):1422-8. doi: 10.1200/JCO.2009.25.3237. Epub 2010 Feb 8. [http://jco.ascopubs.org/content/28/8/1422.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20142586 PubMed] | ||
==Everolimus== | ==Everolimus== | ||
Revision as of 15:28, 24 May 2013
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Relapsed/Refractory
Bortezomib and Rituximab
Regimen
- Bortezomib (Velcade) 1.6 mg/m2 IV days 1, 8, 15
- Rituximab (Rituxan) 375 mg/m2 IV on days 1, 8, 15, 22 (cycles 1 and 4, only)
28-day cycles x up to 6 cycles
References
- Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10;28(8):1422-8. doi: 10.1200/JCO.2009.25.3237. Epub 2010 Feb 8. link to original article contains verified protocol PubMed
Everolimus
Regimen
- Everolimus (Afinitor) 10 mg PO once per day
28-day cycles, given until progression or unacceptable toxicity
References
- Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10;28(8):1408-14. doi:10.1200/JCO.2009.24.0994. Epub 2010 Feb 8. link to original article contains verified protocol PubMed
Panobinostat
Regimen
- Panobinostat (LBH589) 30 mg PO 3 days per week (Mondays, Wednesdays, and Fridays)
28-day cycles, given until progression of disease
References
- Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303. doi:10.1182/blood-2012-06-439307. Epub 2013 Jan 3. link to original article contains verified protocol PubMed